Cencora, inc. COR.US Overview
COR AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
COR Current Performance
-0.81%
Cencora, inc.
-1.83%
Avg of Sector
-0.40%
S&P500
COR Key Information
COR Revenue by Segments
Browsing restrictions can be lifted for a fee.
COR Net Income
Browsing restrictions can be lifted for a fee.
COR Cash Flow
Browsing restrictions can be lifted for a fee.
COR Profit Margin
Browsing restrictions can be lifted for a fee.
COR PE Ratio River
Browsing restrictions can be lifted for a fee.
COR Financial Forecast
Browsing restrictions can be lifted for a fee.
COR Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
COR Profile
Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Price of COR
COR FAQ
When is COR's latest earnings report released?
The most recent financial report for Cencora, inc. (COR) covers the period of 2025Q2 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating COR's short-term business performance and financial health. For the latest updates on COR's earnings releases, visit this page regularly.
Where does COR fall in the P/E River chart?
According to historical valuation range analysis, Cencora, inc. (COR)'s current price-to-earnings (P/E) ratio is 34.86, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of COR?
According to the latest financial report, Cencora, inc. (COR) reported an Operating Profit of 1.03B with an Operating Margin of 1.37% this period, representing a growth of 86.65% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is COR's revenue growth?
In the latest financial report, Cencora, inc. (COR) announced revenue of 75.45B, with a Year-Over-Year growth rate of 10.29%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does COR have?
As of the end of the reporting period, Cencora, inc. (COR) had total debt of 7.86B, with a debt ratio of 0.11. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does COR have?
At the end of the period, Cencora, inc. (COR) held Total Cash and Cash Equivalents of 1.98B, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does COR go with three margins increasing?
In the latest report, Cencora, inc. (COR) achieved the “three margins increasing” benchmark, with a gross margin of 4.1%%, operating margin of 1.37%%, and net margin of 1%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess COR's profit trajectory and future growth potential.
Is COR's EPS continuing to grow?
According to the past four quarterly reports, Cencora, inc. (COR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 3.7. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of COR?
Cencora, inc. (COR)'s Free Cash Flow (FCF) for the period is 3.22B, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 425.08% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of COR?
The latest valuation data shows Cencora, inc. (COR) has a Price-To-Earnings (PE) ratio of 34.86 and a Price/Earnings-To-Growth (PEG) ratio of 0.4. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.